November 16, 2011
Genzyme, a Sanofi company, and Cystic Fibrosis Foundation Therapeutics Inc., the nonprofit affiliate of the Cystic Fibrosis Foundation, today announced a research agreement to support the discovery of new drugs to treat people with the most common mutation found in patients with CF, Delta F508.
The program's focus is to identify compounds known as "correctors," which may aid in the ability of the malfunctioning
In this collaboration, researchers will evaluate different compound libraries for correctors for Delta F508, and will take advantage of the vast compound libraries of both Genzyme and Sanofi. The research will take place throughout several Genzyme and Sanofi R&D facilities globally. Genzyme brings to the collaboration more than 20 years' experience exploring treatments for people living with CF. The company's efforts have ranged from improved molecular diagnostics to clinical trials with a
"We are delighted to enter into a research collaboration with Genzyme, a company that has long dedicated itself to improving the lives of people with rare diseases," said Robert J. Beall, Ph.D., president and CEO of the CF Foundation. "Genzyme's capabilities and resources will help the CF Foundation accelerate its effort to find drugs to treat the most common mutation in CF and have the greatest impact on those with this disease."
"While there has been great momentum recently in cystic fibrosis research, there is still great unmet need," said Genzyme's president and CEO, David Meeker, MD. "Together with the CF Foundation, we look forward to working to accelerate the pace of discovery on behalf of CF patients around the world."
- Explore other CF drugs in development in this new interactive pipeline.